AveXis, Inc.
AveXis, Inc. (AVXS): 1 pipeline candidate · ~11 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.1 months
D/E 0.17 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for AveXis, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$589.6M
Quarterly Burn
$160.6M
Runway
11.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| avxs-101 | Phase 1 |
Frequently asked questions
How many drug candidates are in AveXis, Inc.'s pipeline?
AveXis, Inc. (AVXS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is AveXis, Inc.'s lead drug candidate?
AveXis, Inc.'s most advanced tracked candidate is avxs-101 (Phase 1) for Spinal muscular atrophy (SMA) Type 2.
What is AveXis, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AveXis, Inc. has approximately 11.1 months of cash runway.
Get the full picture on AveXis, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.